BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27487741)

  • 21. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
    Seidman JD; Kurman RJ
    Am J Surg Pathol; 1996 Nov; 20(11):1331-45. PubMed ID: 8898837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis.
    Seidman JD; Savage J; Krishnan J; Vang R; Kurman RJ
    Int J Gynecol Pathol; 2020 Jan; 39(1):43-54. PubMed ID: 30480646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
    Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
    Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas.
    Bell KA; Smith Sehdev AE; Kurman RJ
    Am J Surg Pathol; 2001 Apr; 25(4):419-32. PubMed ID: 11257616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae.
    Silva EG; Deavers MT; Malpica A
    Int J Gynecol Pathol; 2010 Nov; 29(6):507-12. PubMed ID: 20881864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component.
    Slomovitz BM; Caputo TA; Gretz HF; Economos K; Tortoriello DV; Schlosshauer PW; Baergen RN; Isacson C; Soslow RA
    Am J Surg Pathol; 2002 May; 26(5):592-600. PubMed ID: 11979089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations.
    Nilforoushan N; Liu L; Finkelman BS; Andersen J; Liu Y; James J; Hung CF; Wu TC; Vang R; Xing D
    Int J Gynecol Pathol; 2023 Mar; 42(2):182-191. PubMed ID: 35348533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
    Lee KR; Castrillon DH; Nucci MR
    Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary.
    Bell KA; Kurman RJ
    Am J Surg Pathol; 2000 Nov; 24(11):1465-79. PubMed ID: 11075848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation.
    Nakai G; Yamada T; Yamamoto K; Hirose Y; Ohmichi M; Narumi Y
    J Ovarian Res; 2018 Jan; 11(1):7. PubMed ID: 29321056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors.
    Burks RT; Sherman ME; Kurman RJ
    Am J Surg Pathol; 1996 Nov; 20(11):1319-30. PubMed ID: 8898836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serous ovarian tumors].
    Diebold J
    Pathologe; 2014 Jul; 35(4):314-21. PubMed ID: 24916775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
    Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
    Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
    Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.